%20(1)-808x422.webp)
Smart Decisions: The G-FINDER 2024 Neglected Disease R&D report
Tough choices in global health need people who will make smart decisions. This report provides strong data and solid insights to empower the community.
Hubs
The Investment Landscape Hub
Powered by G-FINDER, this hub is your go-to resource for data and analysis on the funding landscape for global health R&D. This is where you'll find all the G-FINDER reports across neglected disease, emerging infectious diseases and sexual & reproductive health.
Hub Editors
Dr Paul Barnsley
Research and Analysis Lead
Dr Sabastine Wakdok
Director of Research
Mapping the landscape
What is impacting global health?
Every year the G-FINDER project delivers the latest comprehensive data on global investment into R&D of new products to prevent, diagnose, control or cure diseases which kill millions. We analyse the funding landscape to show you where the money is coming from and where it's going. We reveal areas of growth, areas of decline and where we have gaps. We track which products have entered or moved along the pipeline thanks to this investment. This hub collates this huge resource of data and analysis in one place, where you can explore the findings and assess the implications.
The 2024 G-FINDER Neglected Disease R&D report63%
of global funding came from governments in 2023
Which is a record low
83%
of global philanthropic investment in 2023
Is from the Gates Foundation
12%
of the global vaccine funding in 2023 is for TB
Up from 5% in 2018
Spotlight on latest reports
Relied on by governments, NGOs, private and philanthropic funders, product developers and global health advocates worldwide to inform decisions on R&D funding.
Read more
G-FINDER 2024 Landscape of Emerging Infectious Disease Research & Development report: Lessons Learned
This is our third report analysing global investment into research and development for emerging infectious diseases
G-FINDER 2023 Sexual & Reproductive Health Research & Development report: Beyond Spillovers
The 2023 report on investment in R&D for reproductive, sexual, maternal or women's health issues produced through the G-FINDER project
30 January 2025: Launch of the Smart Decisions report
Online webinar
Join us for a dynamic discussion on the tough choices that need to be made in global health R&D. Bookmark this page for the recording and summary which we'll post soon after.
Register now
All resources in this hub
5 min read
Neglected disease funders
Who was funding what in 2023 and what does this mean for the future?
5 min read
Funding by disease
How much R&D funding for which diseases did we see in 2023?
5 min read
Discussion
Key messages from the 2023 global health R&D funding landscape and our recommendations for funders.
5 min read
Introduction
Start here for the 2024 G-FINDER Neglected Disease R&D report - entitled Smart Decisions.
45 min read
G-FINDER 2024 Landscape of Emerging Infectious Disease Research & Development report: Lessons Learned
This is our third report analysing global investment into research and development for emerging infectious diseases
45 min read
G-FINDER 2023 Neglected Disease Research & Development report: The Higher Cost of Lower Funding
This report contains an overview of the changes in neglected disease funding in 2022 and, for the first time, adds comprehensive coverage of the product pipeline in each disease area
45 min read
G-FINDER 2023 Sexual & Reproductive Health Research & Development report: Beyond Spillovers
The 2023 report on investment in R&D for reproductive, sexual, maternal or women's health issues produced through the G-FINDER project
45 min read
G-FINDER 2022 Neglected Disease Research & Development report: The Status Quo Won't Get Us There
Funding for neglected tropical diseases has been stagnating for more than a decade. We need a new model for attracting R&D funding, as the existing approach consistently fails to deliver investment at the scale required.
45 min read
G-FINDER 2022 Landscape of Emerging Infectious Disease Research & Development report: From Pandemic Response to Pandemic Resilience
This is our second report analysing global investment into research and development for emerging infectious diseases